INmune Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-49.89	-42.08	-30.01	-27.3	-30.34	-12.1
Stock-Based Compensation	8.35	7.61	7.37	7.15	4.8	3.11
Other Adjustments	8.26	0.08	0.22	0.33	0.13	-
Changes in Accounts Payable	-3.12	-1.37	2.72	1.4	2.26	1.08
Changes in Other Operating Activities	-2.2	2.41	7.72	-4.27	-5.35	-1.03
Operating Cash Flow	-30.65	-33.36	-11.98	-22.69	-28.5	-8.94
Capital Expenditures	-0.55	-	-	-	-	-
Purchases of Intangible Assets	-	-	-	-	-15	-
Investing Cash Flow	-0.55	-	-	-	-15	-
Long-Term Debt Issued	-	-	-	-	14.95	-
Long-Term Debt Repaid	-2.5	-10	-5	-	-	-
Net Long-Term Debt Issued (Repaid)	-2.5	-10	-5	-	14.95	-
Issuance of Common Stock	38.96	28.21	0.78	0.73	81.41	24.91
Repurchase of Common Stock	-	-	-	-	-	-1.01
Net Common Stock Issued (Repurchased)	38.96	28.21	0.78	0.73	81.41	23.9
Financing Cash Flow	25.47	18.21	-4.23	0.73	96.36	23.9
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.27	0.22	-0.1	-0.7	-0.01	0.02
Net Cash Flow	-5.82	-14.93	-16.31	-22.66	52.84	14.97
Free Cash Flow	-31.2	-33.36	-11.98	-22.69	-28.5	-8.94
FCF Margin	-	-238292.86%	-7729.03%	-6065.78%	-15748.07%	-81300.00%
Free Cash Flow Per Share	-1.32	-1.67	-0.67	-1.27	-1.77	-0.75
Levered Free Cash Flow	-58.41	-51.05	-24.57	-30.16	-18.48	-12.06
Unlevered Free Cash Flow	-57.4	-41.6	-19.31	-28.82	-32.24	-12.18

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q